1 January 2021 in Emerging Microbes & Infections
Clostridioides difficile sequence type (ST) 37 (ribotype 017) is one of the most prevalent genotypes circulating in China. However, its genomic evolution and virulence determinants were rarely explored. Whole-genome sequencing, phylogeographic and phylogenetic analyses were conducted for C. difficile ST37 isolates. The 325 ST37 genomes from six continents, including North America (n = 66), South America (n = 4), Oceania (n = 7), Africa (n = 9), Europe (n = 138) and Asia (n = 101), were clustered into six major lineages, with region-dependent distributions, harbouring an array of antibiotic-resistance genes. The ST37 strains from China were divided into four distinct sublineages, showing five importation times and international sources. Isolates associated with severe infections exhibited significantly higher toxin productions, tcdB mRNA levels, and sporulation capacities (P < 0.001). Kyoto Encyclopedia of Genes and Genomes analysis showed 10 metabolic pathways were significantly enriched in the mutations among isolates associated with severe CDI (P < 0.05). Gene mutations in glycometabolism, amino acid metabolism and biosynthesis virtually causing instability in protein activity were correlated positively to the transcription of tcdR and negatively to the expression of toxin repressor genes, ccpA and codY. In summary, our study firstly presented genomic insights into genetic characteristics and virulence association of C. difficile ST37 in China. Gene mutations in certain important metabolic pathways are associated with severe symptoms and correlated with higher virulence in C. difficile ST37 isolates.
1 October 2024 in Nature Communications
The seventh cholera pandemic started in 1961 in Indonesia and spread across the world in three waves in the decades that followed. Here, we utilised genomic evidence to detail the first wave of the seventh pandemic. Genomes of 22 seventh pandemic Vibrio cholerae isolates from 1961 to 1979 were completely sequenced. Together with 152 publicly available genomes from the same period, they fell into seven phylogenetic clusters (CL1–CL7). By multilevel genome typing (MGT), all were assigned to MGT2 ST1 (Wave 1) except three isolates in CL7 which were typed as MGT2 ST2 (Wave 2). The Wave 1 seventh pandemic expanded in two stages, with Stage 1 (CL1–CL5) spread across Asia and Stage 2 (CL6 and CL7) spread to the Middle East and Africa. Three non-synonymous mutations, one each, in three regulatory genes, csrD (global regulator), acfB (chemotaxis), and luxO (quorum sensing) may have critically contributed to its pandemicity. The three MGT2 ST2 isolates in CL7 were the progenitors of Wave 2 and evolved from within Wave 1 with acquisition of a novel IncA/C plasmid. Our findings provide new insight into the evolution and transmission of the early seventh pandemic, which may aid future cholera prevention and control.
2 September 2025 in Microbiology Spectrum
Toxigenic Clostridioides difficile is the cause of C. difficile infection, highlighting the critical need for rapid and easy-to-use detection. In this study, a multiple cross displacement amplification (MCDA) assay was developed to detect toxigenic C. difficile and evaluated against real-time PCR and VIDAS C. difficile toxin A & B assay (CDAB). The results showed that MCDA targeting the C. difficile tcdB gene had a limit of detection (LOD) of 12.5 fg (2.5 copies of genomic DNA) per reaction with no non-specific amplification from other pathogens. The LOD for MCDA was the same as real-time PCR but had significantly faster detection time, detecting 500 pg and 12.5 fg per reaction in 5.7 ± 0.5 and 21.35 ± 2.2 min, respectively. Among 201 stool samples, MCDA identified 40 positive for toxigenic C. difficile with a shorter average detection time of 16.08 ± 4.62 min compared to real-time PCR (39.82 ± 4.44 min). Using cell cytotoxicity neutralization assays as reference, MCDA demonstrated a significantly higher specificity (92.4%) and a positive predictive value (67.5%) than real-time PCR (80.8 and 43.2%, respectively; P < 0.05). MCDA also had a significantly higher sensitivity (93.1%) and a negative predictive value (98.8%) compared to VIDAS CDAB (34.5 and 90.1%, respectively; P ≤ 0.001). This was also higher compared to real-time PCR (86.2 and 97.2%, P > 0.05). MCDA offers a promising screening alternative for point-of-care testing to detect toxigenic C. difficile and effectively rule out non-toxigenic C. difficile . It is rapid, easy to use, and has a balanced performance, making it applicable in clinical and community settings, particularly in resource-limited settings. IMPORTANCE: Rapid detection of toxigenic Clostridioides difficile is important for early intervention and outbreak control of C. difficile infection in primary healthcare facilities. This study developed an MCDA assay and showed that it was rapid, sensitive, user-friendly, and a suitable point-of-care screening alternative for accurately detecting toxigenic C. difficile . MCDA had the same sensitivity as real-time PCR while providing significantly faster turnaround times and improved specificity along with positive and negative predictive values. Its balanced performance and rapid detection capability make it well-suited for clinical detection of toxigenic C. difficile and point-of-care testing in communities, particularly in resource-limited settings, and for potential self-testing.
12 December 2023 in Microbiology Spectrum
Vibrio cholerae O1 has caused cholera pandemics. Non-pandemic V. cholerae O1 strains, which are genetically distinctive from the pandemic clones, have been isolated from both human infections and the environment. We aimed to better understand the non-pandemic O1 strains and their pandemic potential. We sequenced 109 non-pandemic O1 isolates from Zhejiang, China (from 1963 to 1996) and compared them with 62 publicly available non-pandemic O1 genomes. The isolates from Zhejiang can be classified into three lineages (L1–L3). All grouped together with L3 sharing the most recent common ancestor with the pandemic clones. L2 and L3 emerged in the 1960s while L1 emerged in the 1970s. L1 and L2 disappeared after the 1990s, but L3 persisted until recently. All isolates contained the type VI secretion system. The Vibrio pathogenicity island was present in all L3 isolates, whereas the type III secretion system was present in all L1 isolates. L2 did not carry any unique virulence genes. An intact CTXφ was present in only two L3 isolates. An intact Vibrio seventh pandemic island 1 was present in only three L3 isolates. The
bla
CARB-7
gene was identified in 96.3% of L2 isolates. Each of the non-pandemic O1 lineages has unique properties contributing to their capacity to cause disease. Our findings offer new insight into the evolution of O1 V. cholerae for cholera prevention and control. IMPORTANCE: It is well recognized that only Vibrio cholerae O1 causes cholera pandemics. However, not all O1 strains cause pandemic-level disease. In this study, we analyzed non-pandemic O1 V. cholerae isolates from the 1960s to the 1990s from China and found that they fell into three lineages, one of which shared the most recent common ancestor with pandemic O1 strains. Each of these non-pandemic O1 lineages has unique properties that contribute to their capacity to cause cholera. The findings of this study enhanced our understanding of the emergence and evolution of both pandemic and non-pandemic O1 V. cholerae .
12 February 2026 in Emerging Microbes & Infections
Linezolid-resistant Clostridioides difficile, conferred by the acquisition of cfr-like genes, has been reported in Europe and America. However, the emergence of linezolid resistance in C. difficile in the Asia-Pacific region and its impacts on C. difficile pathogenicity remain unclear. In this study, 881 C. difficile isolates from the Asia-Pacific region were screened for cfr-like genes. Whole genome sequencing was performed on 16 cfr-like gene-positive isolates from four countries. Thirteen isolates possessed cfr(B), which was located within Tn6218, while three isolates possessed cfr(C), which was located within the integrative and conjugative elements (ICE) F548 and DA275. Fourteen (87.5%, 14/16) of the cfr-like gene-positive isolates were resistant to linezolid. In comparison to the two isolates susceptible to linezolid, these 14 isolates exhibited significantly higher mRNA expression levels of cfr(B) and cfr(C), along with significantly higher bacterial density at 12 h. Conversely, they demonstrated reduced abilities for sporulation and biofilm formation. After the cfr(B) gene was knocked down by the CRISPR interference, the C. difficile strain presented lower bacterial density at 12 h, higher toxin production and stronger sporulation and biofilm formation abilities. Our findings reveal the emergence of cfr-like genes C. difficile isolates in the Asia-Pacific region, highlighting that cfr-like genes not only mediate linezolid resistance but also contribute to regulating pathogenic potential. Linezolid resistance in CDI should be closely monitored in specific patients.
25 November 2025 in Communications Biology
The incidence of Clostridioides difficile infection (CDI) has been rising globally in recent years. Treating CDI is complicated by antibiotic-induced disruption of the normal gut microbiota, which promotes CDI recurrence and increases the risk of therapeutic failure. We used an AI-assisted approach to screen small molecule inhibitors targeting the receptor binding domain of toxin B (TcdB). Biliverdin (BV) had strong binding affinities with all TcdB variants. In vitro results showed that BV exhibited no cytotoxic effects on cells and didn’t affect growth of C. difficile , yet markedly suppressed cytotoxic effects induced by TcdB1-4. Encapsulating BV in intestinal epithelial cell-derived extracellular vesicles (I-EVs) significantly recovered body weight, enhanced survival rate, reduced TcdB load, and alleviated intestinal lesions in treated gerbils. Notably, BV treatment not only restored the abundance of gut microbiota but also significantly increased the quantity of gut-beneficial Firmicutes . BV also exerted its anti-CDI effect by restoring the short-chain fatty acid metabolic network. Our findings indicate that BV shows promise as a natural small-molecule therapeutic that attenuates broad-spectrum TcdB-induced injuries, highlighting its potential for clinical translation in CDI treatment.